A Prospective Evaluation of Radiofrequency Ablation in the Treatment of Relapsed Graves' Disease.
Launched by THE UNIVERSITY OF HONG KONG · May 13, 2024
Trial Information
Current as of March 14, 2025
Active, not recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • (a) age older than 18 years,
- • (b) relapsed Graves' disease despite an adequate ATD treatment for 18 months or more and
- • (c) absence of vocal cord immobility.
- Exclusion Criteria:
- • (a) patients who prefer or indicated for surgery,
- • (b) head and/or neck disease preventing hyperextension of the neck,
- • (c) history of thyroid cancer or other malignant tumors in the neck region,
- • (d) history of neck irradiation,
- • (e) moderate to severe Graves' ophthalmopatty,
- • (f) large compressive goiter
- • (g) pregnancy or lactation, and
- • (h) any contraindication related to intravenous moderate sedation.
Trial Officials
Matrix, Man Him Fung, MBBS
Principal Investigator
The University of Hong Kong
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
